{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:58:45Z","timestamp":1780948725777,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00774-025-01683-y","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:38:50Z","timestamp":1767429530000},"page":"336-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bone fragility and atypical femoral fractures in SLE: role of disease activity, infection, and treatment"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3952-7163","authenticated-orcid":false,"given":"Hiroe","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Watarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"1683_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329","journal-title":"Ann Rheum Dis"},{"key":"1683_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","volume":"42","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S et al (2024) The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab 42:143\u2013154","journal-title":"J Bone Miner Metab"},{"key":"1683_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00296-019-04407-4","volume":"39","author":"H Sato","year":"2019","unstructured":"Sato H, Kondo N, Wakamatsu A, Kobayashi D, Nakatsue T et al (2019) High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Rheumatol Int 39:1803\u20131810","journal-title":"Rheumatol Int"},{"key":"1683_CR4","doi-asserted-by":"crossref","unstructured":"Sato H, Kondo N, Kurosawa Y, Hasegawa E, Wakamatsu A, et al. (2024) Incidence and clinical course of femoral localized periosteal thickening and atypical femoral fracture over a 10-year period in patients with autoimmune inflammatory rheumatic disease (in eng). JBMR Plus 8:ziae090","DOI":"10.1093\/jbmrpl\/ziae090"},{"key":"1683_CR5","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"1683_CR6","first-page":"273","volume":"12","author":"N Kondo","year":"2015","unstructured":"Kondo N, Yoda T, Fujisawa J, Arai K, Sakuma M et al (2015) Bilateral atypical femoral subtrochanteric fractures in a premenopausal patient receiving prolonged bisphosphonate therapy: evidence of severely suppressed bone turnover. Clin Cases Miner Bone Metab 12:273\u2013277","journal-title":"Clin Cases Miner Bone Metab"},{"key":"1683_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1620\/tjem.243.247","volume":"243","author":"N Kondo","year":"2017","unstructured":"Kondo N, Fukuhara T, Watanabe Y, Miyasaka D, Yamamoto N et al (2017) Bone formation parameters of the biopsied ilium differ between subtrochanteric and diaphyseal atypical femoral fractures in bisphosphonate-treated patients. Tohoku J Exp Med 243:247\u2013254","journal-title":"Tohoku J Exp Med"},{"key":"1683_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bone.2014.04.012","volume":"64","author":"K Iwata","year":"2014","unstructured":"Iwata K, Mashiba T, Hitora T, Yamagami Y, Yamamoto T (2014) A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy. Bone 64:183\u2013186","journal-title":"Bone"},{"key":"1683_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6624414","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Kondo N, Fukuhara T, Imai N, Yamada M et al (2021) Histopathological finding of microdamage accumulation in atypical subtrochanteric femoral fracture. Case Rep Orthop. https:\/\/doi.org\/10.1155\/2021\/6624414","journal-title":"Case Rep Orthop"},{"key":"1683_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"1683_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH et al (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383:743\u2013753","journal-title":"N Engl J Med"},{"key":"1683_CR12","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/jbmr.2918","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:1910","journal-title":"J Bone Miner Res"},{"key":"1683_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1210\/er.2018-00001","volume":"40","author":"DM Black","year":"2019","unstructured":"Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N (2019) Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev 40:333\u2013368","journal-title":"Endocr Rev"},{"key":"1683_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00774-014-0591-9","volume":"33","author":"Y Saita","year":"2015","unstructured":"Saita Y, Ishijima M, Mogami A, Kubota M, Baba T et al (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33:311\u2013318","journal-title":"J Bone Miner Metab"},{"key":"1683_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/mr\/roac062","volume":"33","author":"H Sato","year":"2023","unstructured":"Sato H, Kondo N, Takai C, Kurosawa Y, Hasegawa E et al (2023) Risks of femoral localized periosteal thickening in patients with autoimmune inflammatory rheumatic diseases. Mod Rheumatol 33:803\u2013810","journal-title":"Mod Rheumatol"},{"key":"1683_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00198-015-3382-9","volume":"27","author":"H Sato","year":"2016","unstructured":"Sato H, Kondo N, Wada Y, Nakatsue T, Iguchi S et al (2016) The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. Osteoporos Int 27:1217\u20131225","journal-title":"Osteoporos Int"},{"key":"1683_CR17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725","journal-title":"Arthritis Rheum"},{"key":"1683_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00774-021-01236-z","volume":"39","author":"S Soen","year":"2021","unstructured":"Soen S, Kaku M, Okubo N, Touzeni S, Saito K et al (2021) Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. J Bone Miner Metab 39:1019\u20131030","journal-title":"J Bone Miner Metab"},{"key":"1683_CR19","doi-asserted-by":"publisher","first-page":"7750","DOI":"10.1038\/s41598-024-58463-3","volume":"14","author":"A Manabe","year":"2024","unstructured":"Manabe A, Sada RM, Miyake H, Akebo H, Tsugihashi Y et al (2024) An observational study to identify causative factors for not using hydroxychloroquine in systemic lupus erythematosus. Sci Rep 14:7750","journal-title":"Sci Rep"},{"key":"1683_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00198-015-3449-7","volume":"27","author":"X Wang","year":"2016","unstructured":"Wang X, Yan S, Liu C, Xu Y, Wan L et al (2016) Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int 27:1413\u20131423","journal-title":"Osteoporos Int"},{"key":"1683_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-019-0667-1","volume":"15","author":"C Gu","year":"2019","unstructured":"Gu C, Zhao R, Zhang X, Gu Z, Zhou W et al (2019) A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors. Arch Osteoporos 15:1","journal-title":"Arch Osteoporos"},{"key":"1683_CR22","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/rheumatology\/keaa705","volume":"60","author":"D Garelick","year":"2021","unstructured":"Garelick D, Pinto SM, Farinha F, Pires T, Khan E et al (2021) Fracture risk in systemic lupus erythematosus patients over 28 years. Rheumatology (Oxford) 60:2765\u20132772","journal-title":"Rheumatology (Oxford)"},{"key":"1683_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/ard.2003.018127","volume":"64","author":"CS Yee","year":"2005","unstructured":"Yee CS, Crabtree N, Skan J, Amft N, Bowman S et al (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus (in eng). Ann Rheum Dis 64:111\u2013113","journal-title":"Ann Rheum Dis"},{"key":"1683_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0961203316664597","volume":"26","author":"G Cramarossa","year":"2017","unstructured":"Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z (2017) Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus 26:365\u2013372","journal-title":"Lupus"},{"key":"1683_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acr.23279","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J et al (2017) American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69:1095\u20131110","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1683_CR26","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G et al (2023) 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 75:2088\u20132102","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01683-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:10:21Z","timestamp":1780945821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01683-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01683-y","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroe Sato received lecture fee from Asahi Kasei Pharma, Daiichi Sankyo Company, Amgen Inc., and Astellas pharma Inc. Naoki Kondo, Tomoya Watarai, Eriko Hasegawa, Ayako Wakamatsu, Yukiko Nozawa, Daisuke Kobayashi, Takeshi Kuroda, and Suguru Yamamoto declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}